Precipitation of porphyria cutanea tarda by imatinib mesylate? [1]

British Journal of Haematology

Volumn 121, Issue 2, 2003, Pages 375-

  Ho, Aloysius Y L ^a   Deacon, Allan ^a   Osborne, Genevieve ^a   Mufti, Ghulam J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Imatinib mesylate; Porphyria cutanea tarda

Indexed keywords

HYDROXYCHLOROQUINE; IMATINIB; PORPHYRIN; UROPORPHYRINOGEN DECARBOXYLASE;

ADULT; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; HUMAN; HUMAN TISSUE; LETTER; MALE; MYELOFIBROSIS; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; RISK FACTOR; SKIN BIOPSY; TREATMENT OUTCOME; URINE LEVEL;

ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PORPHYRIA CUTANEA TARDA; PYRIMIDINES;

EID: 0038217017     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04277.x     Document Type: Letter

References (4)

1. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. & Talpaz, M. (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038-1042.
2. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S. & Sawyers, C.L. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031-1037.
3. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M. & Druker, B. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine. 346, 645-652.
4. Tefferi, A., Mesa, R.A., Gray, L.A., Steensma, D.P., Camoriano, J.K., Elliott, M.A., Pardanani, A., Ansell, S.M., Call, T.G., Colon-Otero, G., Schroeder, G., Hanson, C.A., Dewald, G.W. & Kaufmann, S.H. (2002) Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood, 99, 3854-3856.